USO 23164
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (CB10A)
Disease Types: CAR-T
Available at:
Disease Types: CAR-T
Available at: